Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Filing for WHO Emergency Use Authorisation this month
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The GMP certificate is valid for three years until April 2024.
As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
These media reports are based on incorrect facts and are without any basis.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
